August 2013

Introduction

Novel CNS Imaging Options with Ferumoxytol (A Superparamagnetic Iron Oxide Nanoparticle) as an MR Contrast Agent

Edward A. Neuwelt

Edward A. Neuwelt

MRI is a critical clinical tool that guides treatment decisions for patients with brain tumors and other clinical issues. The current standard gadolinium-based contrast agents (GBCA) have limitations in medical imaging concerning inconsistent and unreliable measurement of relative cerebral blood volume (rCBV), which is emerging as an important component in accurately diagnosing patients with CNS inflammatory disorders, lymphoma, vascular malformations, and especially CNS tumors. In addition, there are patient populations that cannot receive … more »

Brain

Ferumoxytol and Stroke: Assessing CNS Vascular Disease

Manninger SP, Muldoon LL, Nesbit G, et al. An Exploratory Study of Ferumoxtran-10 Nanoparticles as a Blood-Brain Barrier Imaging Agent Targeting Phagocytic Cells in CNS Inflammatory Lesions. AJNR Am J Neuroradiol 2005;26:2290-300.

Edit Dósa

Edit Dósa

Ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles may have benefit over gadolinium-based contrast agents (GBCA) for neuroimaging. Using ferumoxtran-10 in patients with brain tumors, … more »

Brain

Preclinical and Clinical Studies of Gadolinium-based Contrast Agents to Assess Cerebral Blood Volume – Problem with Vascular Leak

Varallyay P, Nesbit G, Muldoon LL, et al. Comparison of Two Superparamagnetic Viral-Sized Iron Oxide Particles Ferumoxides and Ferumoxtran-10 with a Gadolinium Chelate in Imaging Intracranial Tumors. AJNR Am J Neuroradiol 2002;23:510–19

Seymur Gahramanov

Seymur Gahramanov

This early clinical paper compared 2 different iron oxide nanoparticle contrast agents with gadolinium-based contrast agents (GBCA) using standard MRI sequences to … more »